Literature DB >> 17596718

Frontotemporal dementia with tau pathology.

Laura Gasparini1, Beatrice Terni, Maria Grazia Spillantini.   

Abstract

Tau is a microtubule-associated protein involved in microtubule assembly and stabilization. Filamentous deposits made of tau constitute a major defining characteristic of several neurodegenerative diseases known as tauopathies including Alzheimer's disease. The involvement of tau in neurodegeneration has been clarified by the identification of genetic mutations in the tau gene in cases with familial frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17). Although the mechanism through which tau mutations lead to neuronal death is still unresolved, it is clear that tau mutations lead to formation of tau filaments that have a different morphology, contain different types of tau isoforms and produce distinct tau deposits. The range of tau pathology identified in FTDP-17 recapitulates the tau pathology present in sporadic tauopathies and indicates that tau dysfunction plays a major role also in these diseases. 2007 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17596718     DOI: 10.1159/000101848

Source DB:  PubMed          Journal:  Neurodegener Dis        ISSN: 1660-2854            Impact factor:   2.977


  24 in total

1.  Activity-Dependent Reconnection of Adult-Born Dentate Granule Cells in a Mouse Model of Frontotemporal Dementia.

Authors:  Julia Terreros-Roncal; Miguel Flor-García; Elena P Moreno-Jiménez; Noemí Pallas-Bazarra; Alberto Rábano; Nirnath Sah; Henriette van Praag; Damiana Giacomini; Alejandro F Schinder; Jesús Ávila; Maria Llorens-Martín
Journal:  J Neurosci       Date:  2019-05-27       Impact factor: 6.167

Review 2.  Tau splicing and the intricacies of dementia.

Authors:  Athena Andreadis
Journal:  J Cell Physiol       Date:  2012-03       Impact factor: 6.384

3.  The MAPT H1 haplotype is associated with tangle-predominant dementia.

Authors:  Ismael Santa-Maria; Aya Haggiagi; Xinmin Liu; Jessica Wasserscheid; Peter T Nelson; Ken Dewar; Lorraine N Clark; John F Crary
Journal:  Acta Neuropathol       Date:  2012-07-17       Impact factor: 17.088

4.  Kinesin-1 transport reductions enhance human tau hyperphosphorylation, aggregation and neurodegeneration in animal models of tauopathies.

Authors:  Tomás L Falzone; Shermali Gunawardena; David McCleary; Gerald F Reis; Lawrence S B Goldstein
Journal:  Hum Mol Genet       Date:  2010-09-03       Impact factor: 6.150

5.  Saitohin, which is nested within the tau gene, interacts with tau and Abl and its human-specific allele influences Abl phosphorylation.

Authors:  Yan Wang; Lei Gao; Christopher G Conrad; Athena Andreadis
Journal:  J Cell Biochem       Date:  2011-11       Impact factor: 4.429

6.  Behavioral deficit, oxidative stress, and mitochondrial dysfunction precede tau pathology in P301S transgenic mice.

Authors:  Magali Dumont; Cliona Stack; Ceyhan Elipenahli; Shari Jainuddin; Meri Gerges; Natalia N Starkova; Lichuan Yang; Anatoly A Starkov; Flint Beal
Journal:  FASEB J       Date:  2011-08-08       Impact factor: 5.191

7.  Hyperphosphorylated Tau in an α-synuclein-overexpressing transgenic model of Parkinson's disease.

Authors:  Thomas Haggerty; Joel Credle; Olga Rodriguez; Jonathan Wills; Adam W Oaks; Eliezer Masliah; Anita Sidhu
Journal:  Eur J Neurosci       Date:  2011-04-01       Impact factor: 3.386

Review 8.  Faulty RNA splicing: consequences and therapeutic opportunities in brain and muscle disorders.

Authors:  Vittoria Pagliarini; Piergiorgio La Rosa; Claudio Sette
Journal:  Hum Genet       Date:  2017-04-22       Impact factor: 4.132

Review 9.  Neurodegenerative dementia and parkinsonism.

Authors:  A Gabelle; F Portet; C Berr; J Touchon
Journal:  J Nutr Health Aging       Date:  2010-01       Impact factor: 4.075

10.  Fractalkine signaling and Tau hyper-phosphorylation are associated with autophagic alterations in lentiviral Tau and Aβ1-42 gene transfer models.

Authors:  Michaeline L Hebron; Norah K Algarzae; Irina Lonskaya; Charbel Moussa
Journal:  Exp Neurol       Date:  2013-01-16       Impact factor: 5.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.